Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of medical device company Tornier (NASDAQ: TRNX ) plummeted 24% today after its quarterly results and outlook disappointed Wall Street.
So what: The stock has rallied nicely in recent months on optimism over accelerating growth, but a third-quarter miss -- loss of $0.18 in EPS was $0.03 worse than analysts expected -- coupled with downbeat guidance is forcing Mr. Market to quickly sober up. While Tornier's revenue increased 15% over the year-ago period, adjusted EBITDA margin slipped 110 basis points to 7.2%, suggesting that its competitive position is weakening.
Now what: Management now sees full-year revenue of $299.2 million-$303.2 million, well below Wall Street's forecast of $317.38 million.
"We believe we have the infrastructure in place to support our double-digit constant currency revenue growth and enhanced operating leverage expectations," CEO Dave Mowry reassured investors.
However, with Tornier shares still sporting a particularly lofty 40-plus price-to-cash flow multiple, I'd wait for an even wider margin of safety before buying into that optimism.
An even juicier growth opportunity
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!